Anemia biomarkers and mortality in hemodialysis patients with or without diabetes: A 10-year follow-up study
Open Access
- 31 January 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (1) , e0280871
Abstract
Background: Many studies have assessed the association between anemia and mortality in hemodialysis but few compared patients with and without diabetes. Our study aims to investigate the impact of hemoglobin and iron parameters on mortality in hemodialysis patients with or without diabetes. Methods: This is a two-center retrospective study that included all adult patients who started hemodialysis between February 2012 and February 2020, followed until January 2021. Averages of hemoglobin, ferritin and transferrin saturation of entire follow-up were recorded. Kaplan Meier survival, log rank test and cox regression analyses were performed to assess the association between anemia biomarkers and mortality. Results: A total of 214 patients were included. Mean age was 67.98 ±12.41 years, mean hemoglobin was 10.92 ±0.75 g/dL, mean ferritin was 504.43 ± 221.42 ng/mL and mean transferrin saturation was 26.23 ±7.77%. Log rank test showed an association between hemoglobin ≥11 g/dL and better survival in patients without diabetes (P = 0.028). Based on cox regression analysis, hemoglobin was associated with all-cause mortality in all patients (HR = 0.66; CI:0.49,0.89; P = 0.007). When comparing patients with and without diabetes, this association remained significant only in patients without diabetes (HR = 0.53; CI:0.37,0.77; P<0.001). Based on different multivariate models, hemoglobin, ferritin and age were independent factors associated with mortality in patients without diabetes. Conclusions: This study showed that hemoglobin ≥11 g/dL is associated with better survival in hemodialysis patients without diabetes but not in those with diabetes. These differences need to be further explored in other countries and settings. An individualization of the hemoglobin target level might be necessary to improve patients’ outcomes.Keywords
This publication has 39 references indexed in Scilit:
- Chronic kidney disease: global dimension and perspectivesThe Lancet, 2013
- Disappearance of Association in Diabetic Patients on Hemodialysis between Anemia and Mortality Risk: The Japan Dialysis Outcomes and Practice Pattern StudyNephron Clinical Practice, 2012
- Hemoglobin Variability and Mortality: Confounding by Disease SeverityAmerican Journal of Kidney Diseases, 2011
- Age, Race, Diabetes, Blood Pressure, and Mortality among Hemodialysis PatientsJournal of the American Society of Nephrology, 2010
- Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) StudyNephrology Dialysis Transplantation, 2010
- Correlates affecting survival in chronic hemodialysis patients: The combined impact of albumin and high hemoglobin levels on improving outcomes, local and national resultsHemodialysis International, 2008
- History-Adjusted Marginal Structural Analysis of the Association between Hemoglobin Variability and Mortality among Chronic Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- Hemoglobin Variability and Mortality in ESRDJournal of the American Society of Nephrology, 2007
- Hemoglobin Level VariabilityClinical Journal of the American Society of Nephrology, 2006
- Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal studyKidney International, 2006